Fig. 1: High SMARCE1 expression associates with 17q21-ter gain, MYCN-amplification, and poor patient prognosis in neuroblastoma. | Oncogene

Fig. 1: High SMARCE1 expression associates with 17q21-ter gain, MYCN-amplification, and poor patient prognosis in neuroblastoma.

From: SMARCE1 promotes neuroblastoma tumorigenesis through assisting MYCN-mediated transcriptional activation

Fig. 1

A SMARCE1 locus on chromosome 17q21-ter region. B SMARCE1 expression was analyzed by immunoblot in SK-N-BE(2)C, IMR32, SK-N-DZ, SH-SY5Y and SH-EP1 neuroblastoma cell lines. C Kaplan–Meier curves showed the probability of overall survival of patients according to SMARCE1 mRNA expression levels in the 66 MYCN-amplified neuroblastoma samples. Data are from the Kocak dataset. D Representative images of immunohistochemical staining of SMARCE1 in neuroblastoma patient tissues. E Quantitative analysis of SMARCE1 protein expression in neuroblastoma patient tissues at INSS stages 1and 2 versus stages 2B and 4. All data were shown as the mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, ns not significant.

Back to article page